Any investor acquiring 5% or more of a public company's stock must disclose it via Schedule 13D (active/activist intent) or 13G (passive investment) — an early signal of major shareholder moves.
Filings (30d)
2848
Companies
1814
With Stated Activist Purpose
266
Leaderboard Filings
98
Data as of 2026-08-28
| Ticker | Company | Filings | Latest Activist Purpose | Last Filed |
|---|---|---|---|---|
| ENHA | Enhanced Group Inc. (f/k/a A Paradise Acquisition Corp.) | 8 | Purchase Agreement. On June 14, 2026, the Issuer entered into the Purchase Agreement pursuant to which the Issuer agreed to issue and sell to the Reporting Person: (A) 1,285,347 shares of Class A Common Stock and (B) accompanying warrants to purchase 1,285,347 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and accompanying Warrants were issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant was $3.89. The Private Placement closed on August 14, 2026, after the effectiveness of the Stockholder Consent (as defined in the Purchase Agreement). Registration Rights Agreement. On June 14, 2026, the Issuer also entered into a registration rights agreement with the Reporting Person (the "Registration Rights Agreement"), pursuant to which the Issuer has agreed to file a registration statement under the Securities Act with the SEC, covering the resale of the Class A Common Stock and the shares of Class A Common Stock underlying the Warrants no later than 30 days following the applicable closing date and to use commercially reasonable efforts to have the registration statement declared effective by the SEC at the earliest possible date but no later than the earlier of the 90th calendar day following the initial filing date of the registration statement, if the SEC notifies the Company that it will "review" the registration statement, and the fifth business day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be "reviewed" or will not be subject to further review. The foregoing description of the Purchase Agreement, the Warrants and the Registration Rights Agreement do not purport to be complete and are each qualified in their entirety by the full text of the form of such agreements, which are attached as exhibits to this Schedule 13D and incorporated herein by reference | 2026-08-20 |
| BETR | Better Home & Finance Holding Company | 6 | This Amendment No. 7 hereby amends and supplements Item 4 of the Schedule 13D by adding the following thereto: "On August 17, 2026, Vishal Garg and affiliated entities (the "Garg Group") filed with the SEC a preliminary consent statement on Schedule 14A, as amended by Amendment No. 1 thereto filed August 18, 2026 and Amendment No. 2 thereto filed August 25, 2026. Such consent statement states that the Garg Group is soliciting consents of the Issuer's stockholders for, among other things, the proposed removal without cause of the incumbent Issuer directors named therein. Such consent statement also states, among other things, that the previous written stockholder consents delivered to the Issuer on August 17, 2026 in connection with the proposed removal of such directors did not constitute a majority of the Issuer's voting power; and that the only consents that will be solicited by the Garg Group for the proposals described in such consent statement will be by way of such consent statement. The Reporting Persons are not affiliated with, and no Reporting Person is a participant in the consent solicitation being conducted by, the Garg Group. The Reporting Persons currently intend, at the appropriate time pursuant to such consent solicitation, to provide their consent to the removal of the directors named therein. The Reporting Persons acquired the Issuer securities reported herein for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending upon various factors, including, without limitation, the Issuer's financial position and strategic direction, developments concerning the Issuer's corporate governance arrangements, overall market, economic, and industry conditions, the trading price of the Issuer's securities, other investment opportunities available to the Reporting Persons, and the liquidity requirements of the Reporting Persons, the Reporting Persons may seek to increase or decrease their holdings of or their economic exposure to the securities of the Issuer. The Reporting Persons may communicate with other stockholders of the Issuer, directors or officers of the Issuer, and/or other persons regarding the Issuer's business, strategy, operations, management, corporate governance, financial position, and other matters concerning the Issuer. Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto, and/or consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D." | 2026-08-25 |
| RNW | ReNew Energy Global plc | 6 | This Amendment amends and supplements Item 4 of the Original Schedule 13D by adding the following: Transaction Agreement On August 11, 2026, the Issuer and a consortium comprising CPP Investments and the founder, Chairman and CEO of the Issuer, Mr. Sumant Sinha (together with CPP Investments, the "Consortium") entered into a Transaction Agreement (the "Transaction Agreement"). Under the terms of the Transaction Agreement, each Share of the Issuer that is not held by the Consortium and their respective affiliates, not held as a treasury share by the Issuer and not a Rollover Share (as defined below) will be transferred to CPP Investments, for cash consideration of US$7.02 per share, without interest and subject to applicable withholding taxes (the "Consideration"), to be implemented by means of a scheme of arrangement sanctioned by the High Court of Justice of England and Wales (the "Court") under Part 26 of the U.K. Companies Act 2006 (the "Scheme" and together with related transactions contemplated by the Transaction Agreement, the "Transaction"). Rather than receiving the Consideration in cash, each shareholder of the Issuer (other than any shareholder residing in India, who may not elect to participate in the Rollover as defined below) may elect to retain all of its shares of the Issuer, which will remain outstanding following the Scheme and in respect of which no Consideration or other distributions will be paid (a "Rollover", the shares so retained (and subject to the cutbacks described in the Transaction Agreement), the "Rollover Shares", and any Issuer shareholder holding any Rollover Shares, a "Rollover Shareholder"). Irrevocable Undertaking In connection with the Transaction, JERA Power RN B.V. ("JERA Power") has delivered an irrevocable undertaking in favor of the Consortium (the "Irrevocable Undertaking"). Pursuant to the Irrevocable Undertaking, JERA Power undertakes, among other things, to: (i) exercise (or procure the exercise of) all voting rights attaching to its Shares in favor of the Scheme, the Transaction and the related resolutions (and against any resolution to adjourn the relevant shareholder meetings, amend the Scheme, or which is likely to result in a condition of the Scheme not being fulfilled, impede or frustrate the Scheme, or prevent the Scheme from becoming effective); (ii) if the Transaction is implemented by way of a takeover offer, accept that offer in respect of its Shares; (iii) elect to participate in the Rollover in respect of all of its Shares; (iv) refrain from disposing of, or dealing in, its Shares, from acquiring further securities in the Issuer, from entering into third-party arrangements relating to its Shares and from taking any action that would restrict its ability to control the exercise of rights attaching to its Shares, in each case, other than pursuant to the Transaction; and (v) cooperate in the implementation of the Reorganization of the Issuer (as defined below) to be undertaken after the Effective Time of the Scheme (as defined below) and enter into the related Reorganization Deed (as defined below) and the Shareholders' Agreement (as defined below) to be entered into in connection with the Transaction, and provide reasonable cooperation in connection with obtaining required regulatory clearances (subject to customary confidentiality and privilege carve-outs). The Irrevocable Undertaking will lapse in specified circumstances, including if the Transaction Agreement is terminated, if the Scheme lapses or is withdrawn, if the Scheme is not effective (or the offer is not unconditional) by the specified long-stop time, or if a competing offer for the entire issued and to-be-issued share capital of the Issuer becomes effective or is declared unconditional. The foregoing description of the Irrevocable Undertaking does not purport to be complete and is qualified in its entirety by reference to the full text of the Irrevocable Undertaking, a copy of which is filed as Exhibit 99.8 to this Schedule 13D and is incorporated herein by reference. Pursuant to Section 13(d) of the Act, by virtue of the Irrevocable Undertaking described in this Schedule 13D, the Consortium may be deemed to be a member of a "group" with JERA Power. However, the Reporting Persons expressly disclaim beneficial ownership of the Shares beneficially owned by the Consortium, their affiliates or any other reporting person(s). Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that the Reporting Persons beneficially own any Shares that are beneficially owned by the Consortium, their affiliates or any other reporting person(s). The Reporting Persons are only responsible for the information contained in this Schedule 13D and assume no responsibility for information contained in any other Schedule 13D filed by the Consortium, their affiliates or any other reporting person(s). Reorganization and Form of Reorganization Deed Concurrently with the execution of the Transaction Agreement, the Consortium has agreed with JERA Power the form of the Reorganization Deed and the form of the steps plan attached thereto (the "Reorganization Deed"). The Reorganization Deed, which will come into effect at the time at which an order of the Court sanctioning the Scheme is delivered to the Registrar of Companies (the "Effective Time", and the date on which the Effective Time occurs, the "Effective Date"), is the legal framework agreement that will bind the Consortium and Rollover Shareholders to the legal steps (the "Reorganization Steps") that will be undertaken after the Effective Time to effect a reorganization of the Issuer and its subsidiaries (the "Reorganization"), the result of which will be that all shareholders of the Issuer at the Effective Time will become direct shareholders of ReNew Private Limited, a wholly-owned subsidiary of the Issuer ("RPL"). The Reorganization Steps include the below steps, to occur in chronological order: 1. Constitutional Amendments. Once consummation of the Transaction has taken place, the share capital of the Issuer, which is currently comprised of four share classes, will be harmonized into a single class of ordinary shares with pari passu voting and economic rights. 2. The 'Re-Domicile'. Once the Issuer has been re-registered as a private company after consummation of the Transaction, it will transfer at fair market value (which, absent any significant delay between consummation of the Transaction and the re-domicile, is expected to be equivalent to the valuation considered for the purpose of the Transaction) its shares in RPL to each of the Issuer's shareholders on a pro rata basis (based on economic, rather than voting rights), which will have the effect of moving their shareholding to RPL directly. The consideration payable by each shareholder of the Issuer for the transfer of the relevant RPL shares to that shareholder will be left outstanding as a debt owed by that shareholder to the Issuer (the "Consideration Debt"). The Issuer will then immediately declare a distribution to each shareholder of an amount equal to that shareholder's Consideration Debt, and the amount owed by the Issuer to the shareholder under that distribution will be set off against the Consideration Debt so that the two amounts cancel out and no shareholder (nor the Issuer) is required to make a cash payment. The description of the Reorganization and the form of the Reorganization Deed contained in this Item 4 is not intended to be complete. A more detailed description of the Reorganization and the Reorganization Deed will be provided in the Scheme Circular, and a copy of the Reorganization Deed will be attached as an exhibit thereto. Form of the Shareholders' Agreement Concurrently with the execution of the Transaction Agreement, the Consortium has also agreed to a form of shareholders' agreement, which is expected to be entered into at the Effective Time (the "Shareholders' Agreement") by and among the Consortium and certain other continuing shareholders of the Issuer (and the applicable affiliates of the foregoing) that will hold the Rollover Shares (collectively, the "Investors"). The Shareholders' Agreement will govern the ownership and control of the Issuer from and after the Effective Time until the completion of the Reorganization, and RPL, the primary operating subsidiary of the Issuer, from and after the completion of the Reorganization, and will contain, among others, the following material terms (any reference to RPL below is also a reference to the Issuer for the period from and after the Effective Time until the completion of the Reorganization): Governance o Director Appointment Rights: The board of directors of the Issuer (the "Board") and, following completion of the Reorganization Steps, RPL will consist of the number of directors appointed in accordance with the following provisions: (i) the Investor who holds (A) an aggregate ownership interest in RPL or Issuer (as applicable) of more than 50% (on a non-diluted basis), or (B) an aggregate ownership interest of 40% or more and is the single largest ownership interest in RPL or Issuer (as applicable) (on a non-diluted basis) (in either case, the "Controlling Investor") will be entitled to appoint an unlimited number of directors to the Board; (ii) each Investor holding 10% or more of the ownership interest in RPL (on a non-diluted basis) (to the extent not already entitled to appoint an unlimited number of directors under the preceding clause) will be entitled to appoint one director to the Board; (iii) an Investor holding less than 10% of the ownership interest in RPL (on a non-diluted basis) will not hold any director appointment rights; (iv) Mr. Sinha will be entitled to serve as a director on the Board, subject to certain sunset provisions set forth in the Shareholders' Agreement; and (v) any Investor holding 5% or more of the ownership interest in RPL (on a non-diluted basis) will be entitled to appoint a non-voting observer to the Board. Reserved Matters o The Shareholders' Agreement contains customary "reserved matters" provisions, which require the approval of at least 87.6% of the ownership interests in RPL (on a non-diluted basis), in some cases, and at least 95% of the ownership interests in RPL (on a non-diluted basis), in other cases, prior to RPL taking certain specified actions set forth in the Shareholders' Agreement. Transfer Restrictions o The Shareholders' Agreement contains a three-year lock-up binding on all Investors (other than the Controlling Investor), as well as a right of first offer in favor of the Controlling Investor and tag/drag-along rights in respect of transfers by the Controlling Investor. Indian IPO o Within 12 months following the Effective Time, the Board will establish a "Strategic Options Committee" comprised of at least five members, to include (i) Mr. Sinha (for as long as he remains a director), (ii) one member appointed by each Investor holding 12.5% or more of the ownership interests in RPL (on a non-diluted basis) and (iii) a remaining number, sufficient to comprise a majority, appointed by the Controlling Investor, to oversee preparation for the admission of RPL's ordinary shares to a recognized stock exchange. The description of the form of the Shareholders' Agreement contained in this Item 4 is not intended to be complete. A more detailed description of the form of the Shareholders' Agreement will be provided in the Scheme Circular, and a copy of the form of the Shareholders' Agreement will be attached as an exhibit thereto. Other than as described in this Schedule 13D, the Reporting Persons have no plans or proposals of the type referred to in clauses (a) through (j) of Item 4 of Schedule 13D that relate to their investment in the Issuer, although they and their affiliates reserve the right to formulate such plans or proposals in the future. If the Transaction does not proceed, the Reporting Persons will continue to regularly review and assess their investment in the Issuer and depending on market conditions, general economic and industry conditions, the Issuer's business and financial condition and/or other relevant factors, the Reporting Persons may or may not: (i) purchase or sell the Shares or other securities of the Issuer in the future on the open market or in private transactions, or (ii) determine, from time to time, to engage in any of the events set forth in clauses (a) through (j) of Item 4 of Schedule 13D. | 2026-08-11 |
| GNK | GENCO SHIPPING & TRADING LTD | 5 | Item 4 of the Current Schedule 13D is hereby amended and supplemented to add the following: On August 14, 2026, Diana issued a press release announcing that Diana has withdrawn its proposal submitted to the board of directors of the Issuer on June 17, 2026 to acquire all of the issued and outstanding Shares of the Issuer not already owned by Diana for $24.80 in cash (adjusted for the Issuer's recently declared dividend of $0.80 per Share) plus one share of stock of Diana valued at $2.54 based on Diana's 30-day volume-weighted average price as of June 16, 2026 (the "Offer"). Notwithstanding the withdrawal of the Offer, Diana intends to regularly review its investment in the Issuer and consider all potential courses of action in connection with the Issuer and its Shares. Based on such review, as well as other factors, Diana may from time to time and at any time: (i) acquire additional Shares of the Issuer in the open market, in privately negotiated transactions or otherwise; (ii) dispose of any or all of their Shares in the open market, in privately negotiated transactions or otherwise; and (iii) engage in any hedging or similar transactions with respect to the Shares. Any such actions that Diana might undertake may be made at any time without prior notice based on, among other things, Diana's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's Shares; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities available to Diana; and other future developments. Further, Diana may, and reserves the right to, formulate plans or make proposals that could relate to or result in any of the matters listed in Items 4(a) - (j) of Schedule 13D, modify or withdraw any such plan or proposal, or change its intentions with respect to previous plans or proposals, in each case at any time. | 2026-08-27 |
| VBIO | Valion Bio, Inc. | 5 | This Item 4 is not being amended by this Amendment No. 5. | 2026-08-27 |
| SLMT | Brera Holdings PLC | 5 | Item 4 is hereby amended and restated to read as follows: The information set forth or incorporated in Item 3 is hereby incorporated by reference. On the Event Date, Mr. Sade, Ms. Maimon, Ms. Almheiri and Mr. Alnuaimi were appointed to the Board of Directors of the Issuer (the "New Directors"). As directors of the Issuer, each of the New Directors may be able to control the Issuer's business and influence the corporate activities of the Issuer, and expects in the future to discuss and make decisions in the ordinary course of his or her duties regarding plans or proposals with respect to the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D. Depending on the factors discussed herein, each of the New Directors may, from time to time, in their individual capacities, acquire additional Ordinary Shares and/or retain and/or sell all or a portion of the Ordinary Shares held by such person in the open market or in privately negotiated transactions, and/or may distribute Ordinary Shares to be acquired or held by such person to other entities. Any actions that each of the New Directors might undertake will be dependent upon such person's review of numerous factors, including, among other things, the price levels of the Ordinary Shares, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, such person's need for liquidity, and other future developments. Any future acquisitions of Ordinary Shares by each of the New Directors will be subject to the Issuer's policies, including its insider trading policy, as applicable. On the Event Date in connection with the PIPE and the related transactions, the Reporting Persons mutually agreed to dissolve and terminate their informal understanding to act as a "group" for purposes of Regulation 13D solely with respect to the Ordinary Shares of the Issuer. In connection with such determination, each of the Reporting Persons acknowledged and agreed that they are no longer members of a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, effective as of the Event Date, the Reporting Persons no longer may be deemed a "group" within the meaning of Section 13(d)(3) of the Exchange Act and each of Mr. Hirsch, Mr. Sade, Mr. Haklili, Ms. Maimon, Ms. Almheiri and Mr. Alnuaimi separately beneficially owns less than 5% of the outstanding Ordinary Shares of the Issuer and shall cease to be Reporting Persons immediately after the filing of this Amendment. As a result of the Reporting Persons' termination of their informal understanding to act as a "group", except as set forth herein with respect to the New Directors and the Strategic Advisors, none of the Reporting Persons presently has any additional plans or proposals that relate to or that would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D, but depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect their investment in the Issuer at any time. | 2026-08-21 |
| EVGN | EVOGENE LTD. | 5 | Item 4 of the Schedule 13D is hereby amended to add the following at the end thereof: On August 28, 2026, the Reporting Persons disseminated a communication to shareholders entitled "Response of L.I.A. Pure Capital and Invest-Pro to Evogene's August 25, 2026 Press Release." In such communication, the Reporting Persons expressed their views regarding the Issuer's performance, governance and board composition and encouraged shareholders to support the Reporting Persons' nominees for election to the Issuer's board of directors at the Issuer's upcoming annual meeting of shareholders. A copy of such communication is attached hereto as Exhibit 8 and is incorporated herein by reference. . | 2026-08-28 |
| WLDS | Wearable Devices Ltd. | 4 | Item 4 of the Schedule 13D is hereby amended to add the following at the end thereof: On July 31, 2026, the Issuer announced that it entered into a securities purchase agreement with a single institutional investor in a private placement transaction for the purchase and sale of 1,000,000 Ordinary Shares (or Ordinary Share equivalents in lieu thereof) and warrants to purchase up to 1,000,000 Ordinary Shares at a combined purchase price of $3.285 per share and accompanying warrant (the "Private Placement"). On August 1, 2026, the Reporting Persons communicated to the Issuer their objection to the proposed Private Placement and demanded that the Issuer refrain from consummating it. The Reporting Persons asserted, among other things, that the Private Placement would improperly alter the Issuer's capital structure and voting dynamics and affect matters that may be considered by the Issuer's shareholders in connection with the issues previously raised by the Reporting Persons in their prior demand for a special meeting of shareholders. The Reporting Persons further asserted that the Private Placement was not in the best interests of the Issuer and its shareholders and requested that the Issuer take no further action to proceed with the closing of the Private Placement. On August 2, 2026, the Issuer responded and rejected the Reporting Persons' position, asserting, among other things, that the Private Placement was a market-priced financing undertaken in the ordinary course of the Issuer's business, that the Issuer had a continuing need to raise capital to fund its operations and growth, and that the Private Placement would not impair the ability of shareholders to pursue the matters raised in the Reporting Persons' demand for a special meeting of stockholders. On August 2, 2026, the Reporting Persons commenced proceedings in the Economic Department of the District Court of Haifa, Israel (the "Court"), seeking temporary injunctive relief in connection with the Private Placement. On August 2, 2026, the Court issued an ex parte temporary injunction, scheduled a hearing for August 16, 2026, and temporarily prohibited the Issuer from advancing the Private Placement or otherwise modifying its capital structure, pending further order. The Court noted that its decision was issued at a preliminary stage of the proceedings and on an ex parte basis, prior to receiving the positions of the Issuer or the investor in the Private Placement, and that its decision should not be construed as a determination regarding the outcome of the application. The Reporting Persons intend to continue pursuing their rights and remedies in connection with the foregoing matters. | 2026-08-14 |
| LBRDA | Liberty Broadband Corporation | 4 | The information contained in Item 4 of the Schedule 13D is hereby amended to delete last three paragraphs thereof and supplemented to include the following information: As previously disclosed by the Issuer, on November 12, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Charter Communications, Inc. ("Charter"), Fusion Merger Sub 1, LLC, a Delaware limited liability company and wholly owned subsidiary of Charter ("Merger LLC"), and Fusion Merger Sub 2, Inc., a Delaware corporation and wholly owned subsidiary of Merger LLC ("Merger Sub"), whereby, subject to the terms thereof, (i) Merger Sub would merge with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as the surviving corporation and a wholly owned subsidiary of Merger LLC, and (ii) the Merger would be immediately followed by a merger of, the Issuer, as such surviving corporation, with and into Merger LLC (the "Upstream Merger", and together with the Merger, the "Combination"), with Merger LLC surviving the Upstream Merger as the surviving company and a wholly owned subsidiary of Charter. On August 19, 2026, the transactions contemplated by Merger Agreement, including the Combination, were completed, and each share of Series B common stock and the Issuer's Series A common stock, par value $0.01 per share, and the Issuer's Series C common stock, par value $0.01 per share, was automatically converted into 0.2360 of a validly issued, fully paid and nonassessable share of Charter's Class A common stock, par value $0.001 per share, except that cash (without interest) was paid in lieu of fractional shares, and accordingly as a result of the completion of the Merger the Reporting Person disposed of all of the shares of Series B common stock beneficially owned by the Reporting Person and ceased to be the beneficial owner of any shares of Series B common stock. | 2026-08-20 |
| AUR | AURORA INNOVATION INC | 4 | Item 4 is hereby amended and restated as follows: On August 17, 2026, Neben Holdings, LLC, a wholly-owned subsidiary of the Reporting Person, sold 72,000,000 shares of Class A Common Stock to a financial institution in a block sale transaction at a price per share of $6.55 (the "Block Sale"). The Reporting Person periodically reviews its investments in issuers, including the Issuer, and intends to further assess its investment in the Issuer from time to time, on the basis of various factors, including, without limitation, the Issuer's business performance, financial condition, results of operations and prospects, general economic, market and industry conditions, as well as other developments and other investment opportunities available to the Reporting Person and the Issuer. Depending upon the foregoing factors or any other factors that the Reporting Person may deem relevant, the Reporting Person may enter into additional transactions with respect to its investments, including to dispose of part or all of its investment in the Issuer in open market transactions, privately negotiated transactions, via extraordinary transactions such as a merger or otherwise. Any disposition may be effected by the Reporting Person at any time without prior notice, subject to applicable law. The Reporting Person is not currently engaging in discussions with management of the Issuer, the Board, other shareholders of the Issuer or other relevant parties concerning the business, operations, board composition, management, strategy or control, or future plans of the Issuer that would reasonably be expected to result in any of the matters set forth in subparagraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Subject to the foregoing and except as described in this Schedule 13D, neither the Reporting Person nor, to its best knowledge, its directors or executive officers, has any present plan or proposal which relates to, or would result in, any of the events referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Person intends to review its investment in the Issuer on a continuing basis and reserves the right, at any time and from time to time, to review or reconsider its position, change its purpose, take other actions or formulate and implement plans or proposals with respect to any and all matters referred to in clauses (a) through (j) of the instructions to Item 4 of Schedule 13D. | 2026-08-19 |
| GSHD | GOOSEHEAD INSURANCE INC -A | 4 | The Reporting Persons acquired, and presently hold, Class A Common Stock and Class B Common Stock for investment purposes. Each Reporting Person has signed and is a party to the Voting Agreements described in Item 2 above. Except as otherwise described herein and Rule 10b5-1 Trading Plans, none of the Reporting Persons currently has any plans or proposals that would result in or relate to any of the transactions or changes listed in Items 4(a) through 4(j) of Schedule 13D. However, as part of their ongoing evaluation of their investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters or make formal proposals to the board of directors of the Issuer, other stockholders of the Issuer or other third parties regarding such matters. The Reporting Persons reserve the right to acquire additional securities of the Issuer in the open markets, in privately negotiated transactions (which may be with the Issuer or with third parties) or otherwise, to dispose of all or a portion of their holdings of securities of the Issuer or to change their intention with respect to any or all of the matters referred to in this Item 4. | 2026-08-24 |
| VNOM | Viper Energy, Inc. | 3 | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Purchase Agreement On August 3, 2026, the Issuer, as parent, and Viper Energy Partners LP, as buyer, entered into a definitive purchase agreement to acquire certain mineral and royalty interests from the Reporting Persons and related subsidiaries in exchange for 3,654,979 OpCo units and an equivalent number of shares of the Issuer's Class B Common Stock, subject to transaction costs and certain customary post-closing adjustments (the "Purchase Agreement"). The Purchase Agreement is expected to close in September. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of such agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference. | 2026-08-13 |
| MBX | MBX BIOSCIENCES, INC. | 3 | The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer's capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer's business or corporate structure, (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above. | 2026-08-14 |
| GTE | GRAN TIERRA ENERGY INC. | 3 | The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. Brad Virbitsky, a portfolio manager and partner at EPIM, was appointed to the Issuer's Board of Directors as an independent director, effective September 30, 2025, prompting the change from a 13G to a 13D filer. Mr. Virbitsky resigned from the Issuer's Board of Directors on March 12, 2026. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in Item 4(a) through (j) of this Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board of Directors, engaging in discussions with stockholders of the Issuer or third parties, including potential acquirers and service providers, about the Issuer and the Reporting Persons' investment, making proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, including a sale of the Issuer as a whole or in parts, Board of Directors structure (including Board of Directors composition) or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4. | 2026-08-13 |
| INVX | Innovex International, Inc. | 3 | Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: Underwriting Agreement On August 6, 2026, the Issuer entered into an Underwriting Agreement (the "Underwriting Agreement") with Intervale Capital Fund II, L.P., Intervale Capital Fund II-A, L.P., Intervale Capital Fund III, L.P., Amberjack Capital Fund II, L.P., Innovex Co-Invest Fund, L.P., Innovex Co-Invest Fund II, L.P., (collectively, the "Seller Stockholders") and Barclays Capital Inc., as underwriter (the "Underwriter"), relating to the offer and sale by the Selling Stockholders of 5,000,000 shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), at a price to the Underwriter of $28.71 per share (the "Offering"). Amberjack Capital Fund II, L.P. sold 3,706,801 shares of Common Stock to the Underwriter. Innovex Co-Invest Fund II, L.P. sold 865,508 shares of Common Stock to the Underwriter. Innovex Co-Invest Fund, L.P. sold 205,126 shares of Common Stock to the Underwriter. Intervale Capital Fund II, L.P. sold 176,944 shares of Common Stock to the Underwriter. Intervale Capital Fund II-A, L.P. sold 88 shares of Common Stock to the Underwriter. Intervale Capital Fund III, L.P. sold 45,533 shares of Common Stock to the Underwriter. The Offering closed on August 10, 2026. The Underwriting Agreement contains customary representations and warranties, agreements and obligations, closing conditions and termination provisions. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is incorporated by reference as Exhibit 99.1 and is incorporated herein by reference. Lock-up Agreement On August 6, 2026, the Underwriter entered into a lock-up agreement with the Selling Stockholders (the "Lockup Agreement"). Under the Lockup-Agreement, the Selling Stockholders agreed to not and not to cause any affiliates to, during the period beginning on the date of the Lock-up Agreement and ending at the close of business 45 days after the date of the final prospectus relating the Offering, to transfer any Common Stock or any shares underlying such Common Stock without the prior written consent of the Underwriter, subject to certain exceptions. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of Lock-Up Agreement, which is incorporated by reference as Exhibit 99.2 and is incorporated herein by reference. | 2026-08-13 |
| CHTR | CHARTER COMMUNICATIONS, INC. /MO/ | 3 | The information with respect to the consummation of the Transactions and the Ancillary Agreements entered into in connection therewith, as well as the continued Suspension of the Share Repurchases set forth in Items 5(c) and 6 is incorporated herein by reference to the extent responsive to this Item 4. | 2026-08-21 |
| SPHR | Sphere Entertainment Co. | 3 | The Reporting Persons file the long form Schedule 13D pursuant to Section 13d-1 of the Securities Exchange Act of 1934 (the "Act") even though they may be technically eligible to file the short form Schedule G. Because the Reporting Persons may regularly communicate with the Issuer's management, filing the Schedule 13D ensures that these conversations are compliant with the reporting obligations under the Exchange Act. | 2026-08-14 |
| SVRN | OceanPal Inc. | 3 | This Amendment No. 44 is being filed to report that, on (i) as of March 30, 2026, the Reporting Person sold [x] Shares and (ii) on July 31, 2026, the Reporting Persons transferred all of their shares of the Issuer's Series C Preferred Stock to the Issuer for cancellation. As a result of the cancellation of the Series C Preferred Stock and the Reporting Person's prior sales of common stock, the Reporting Person beneficially owns 70,082 Shares, representing approximately 3.74% of the Issuer's outstanding common stock, and no longer beneficially owns any shares of the Issuer's Series C Preferred Stock. Except as described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the matters set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D. | 2026-08-04 |
| TALK | Talkspace, Inc. | 3 | Item 4 of the Existing Schedule 13D is hereby amended and supplemented by adding the following: On August 17, 2026, the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated March 9, 2026, by and among the Issuer, Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub") was consummated. Pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer, and the Issuer continued as the surviving corporation as an indirect wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each outstanding share of Common Stock (other than shares of Company Common Stock to be canceled pursuant to the Merger Agreement and shares with respect to which appraisal rights were properly exercised and not withdrawn under Delaware law) was automatically converted into the right to receive $5.25 in cash, without interest (the "Merger Consideration"). In addition, as of the Effective Time, each stock option granted under the Issuer's equity incentive plans (a "Stock Option") that was vested as of the Effective Time (each, a "Vested Stock Option") was cancelled and converted into the right to receive an amount in cash equal to the excess, if any, of (i) the Merger Consideration over (ii) the per share exercise price of such Vested Stock Option. Each restricted stock unit granted under the Issuer's equity incentive plans ("RSU") that was vested, but not yet settled, as of the Effective Time, was cancelled and converted into the right to receive the Merger Consideration for each RSU. Immediately prior to the Effective Time, each of the Issuer's directors, including Mr. Shachar, resigned from, and ceased serving on, the Issuer's board of directors. Following the Merger, the Reporting Persons no longer beneficially own any securities of the Issuer, nor do they have sole or shared power to vote, direct the vote, dispose or direct the disposition of, any securities of the Issuer. The Common Stock will no longer be listed on Nasdaq and will be deregistered under Section 12(b) of the Exchange Act. | 2026-08-17 |
| AMRX | Amneal Pharmaceuticals, Inc. | 3 | This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D. | 2026-08-12 |
| REPL | Replimune Group, Inc. | 3 | Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosures in Item 5 and Item 6 below are incorporated herein by reference. On August 9, 2026, Replimune Group, Inc. (the "Issuer") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co. (collectively, the "Underwriters"), related to the public offering (the "Offering") of 9,701,490 shares of common stock of the Issuer ("Common Stock") at a price to the public of $12.06 per share and 2,736,340 pre-funded warrants at a price to the public of $12.0599 per pre-funded warrant to purchase shares of Common Stock that are exercisable at any time on a 1-for-1 basis into Common Stock at an exercise price of $0.0001 per warrant with no expiration date, subject to beneficial ownership limitations described in Item 5 (the "2026 $0.0001 Prefunded Warrants"). The Offering closed on August 11, 2026. Pursuant to the Offering, 667 and Life Sciences purchased 126,394 and 2,609,946 2026 $0.0001 Prefunded Warrants, respectively, at the offering price of $12.0599 per pre-funded warrant, totaling 2,736,340 2026 $0.0001 Prefunded Warrants in the aggregate for an aggregate purchase price of $32,999,986.77. Each of 667 and Life Sciences purchased the 2026 $0.0001 Prefunded Warrants with its working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of $0.0001 Prefunded Warrants (as defined in Item 5), exercise of $0.001 Prefunded Warrants (as defined in Item 5), exercise of Stock Options (as defined in Item 5) or otherwise) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control. Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. | 2026-08-14 |
| QSR | Restaurant Brands International Inc. | 3 | Item 4 of Schedule 13D is hereby amended to add the following language: As noted above, 3G RBH delivered to RBI LP an exchange notice to exchange 2,784,549 Exchangeable Units held by 3G RBH. The exchange notice became irrevocable on August 10, 2026 with respect to 2,784,549 Exchangeable Units. As announced by the Issuer on August 10, 2026, upon receipt of the exchange notice, the Issuer, in its capacity as general partner of RBI LP, elected to have RBI LP satisfy the 2026 Exchange by repurchasing 2,784,549 Exchangeable Units for cash. The 2026 Exchange will be effected as of the close of business on August 31, 2026. The Reporting Persons continue to hold 94,373,170 Exchangeable Units, for which they have not submitted any exchange notice. Except as set forth in this Schedule 13D and in connection with the Transactions and the other transactions discussed herein, the Reporting Persons have no plan or proposals that relates to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. | 2026-08-14 |
| EVTL | Vertical Aerospace Ltd. | 3 | This Item 4 of the Schedule 13D is amended and supplemented as follows: The information disclosed in Item 6 of this Amendment No. 9 is incorporated by reference herein. | 2026-08-14 |
| CISS | C3is Inc. | 3 | The Reporting Person involved in the securities described in this Schedule 13D in connection with the Spin-Off Distribution, and intends to review its investment in the Issuer on a continuing basis. The Reporting Person may from time to time acquire additional securities of the Issuer, or retain or sell all or portion of the shares then held by the Reporting Person, in the open market, block trades, underwritten public offerings or privately negotiated transactions. Any actions the Reporting Person might undertake with respect to its investment in the Issuer may be made at any time and from time to time and will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: ongoing evaluation of the Issuer's business, financial condition, operations, prospects and strategic alternatives; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; tax considerations; liquidity of the Issuer's securities; and other factors and future developments. Mr. Vafias serves as the Non-Executive Chairman of the Issuer and John Kostoyannis and George Xiradakis each serve as a director of the Issuer, other shareholders of the Issuer and other relevant parties, which discussions may include matters ranging from the operations and conduct of the Issuer's business to considering or exploring extraordinary corporate transactions including the events listed in Item 4(a) through 4(j) of Schedue 13D. In connection with these discussions, the Reporting Person may, either directly or through one or more affiliates, determine to take any available course of action or to take no course of action and may at any time and from time to time take steps to further or implement such course of action, including any of the events listed in Item 4(a) through 4(j) of Schedule 13D. Any action or actions the Reporting Person may undertake with respect to its investment in the Issuer or the operations and conduct of the Issuer's business will be dependent upon the Reporting Person's review of numerous factors, including those listed above, and the Reporting Person specifically reserves the right to change its intentions, or to formulate plans and proposals, with respect to any or all of the matters described in this paragraph, subject to applicable law and regulations. | 2026-08-28 |
| GRNT | Granite Ridge Resources, Inc. | 3 | Item 4 of the Schedule 13D is hereby amended and supplemented as provided below. Distribution On August 19, 2026, the Fund III Filing Parties effected a pro rata distribution of an aggregate of 14,000,000 shares of Common Stock to their respective limited partners and members, consisting of 4,247,600 shares distributed by Holdco III-A and 9,752,400 shares distributed by Holdco III-B. Voting Agreement On August 25, 2023, GREP GP III (who had voting and dispositive power over Common Stock owned by Fund III and certain of its affiliates), GREP GP II (who had voting and dispositive power over Common Stock owned by Fund II and certain of its affiliates), and Matthew Miller, Griffin Perry, Thaddeus Darden and Kirk Lazarine (collectively, the "Voting Agreement Parties") entered into a Stockholder Voting Agreement (the "Voting Agreement"). Pursuant to the Voting Agreement, the Voting Agreement Parties irrevocably and unconditionally agreed to vote the 75,957,927 shares of Common Stock which the Voting Agreement Parties then held (and any other shares of Common Stock obtained by Voting Agreement Parties in the future) at any annual or special meeting of the Company's stockholders or in connection with any written consent of the Company's stockholders. During the period it was in effect, the Voting Agreement continued indefinitely, but could be terminated on 30 days prior written notice by Voting Agreement Parties holding a majority of the shares of Common Stock subject to the Voting Agreement. In connection with their entry into the Voting Agreement, the Voting Agreement Parties provided GREP GP III an irrevocable voting proxy to vote the shares subject to the Voting Agreement. Additionally, during the term of such agreement, the Voting Agreement Parties agreed not to transfer the shares covered by the Voting Agreement without the consent of GREP GP III, except pursuant to certain limited exceptions. The description of the Voting Agreement contained in this Item 4 is not intended to be complete and is qualified in its entirety by reference to such agreement, which is filed as an exhibit hereto and incorporated by reference herein. Termination of Voting Agreement Effective August 19, 2026, the Voting Agreement Parties terminated the Stockholder Voting Agreement dated August 25, 2023, and it is no longer in effect. As a result, the irrevocable proxy in favor of GREP GP III and the transfer restrictions thereunder have terminated. Open Market Acquisitions and Vesting of Restricted Stock On September 18, 2023, the following Filing Parties made open market acquisitions of shares of Common Stock: Matthew Miller acquired 17,284 shares at prices ranging from $5.73 to $5.85 per share; Griffin Perry acquired 2,000 shares at a price of $5.76 per share, Thaddeus Darden acquired 20,000 shares at a price of $5.74 per share, and Kirk Lazarine acquired 10,000 shares at a price of $5.75 per share. On November 30, 2023, Thaddeus Darden acquired 10,000 shares at a price of $5.92 per share. On December 4, 2023, the following Filing Parties made open market acquisitions of shares of Common Stock: Griffin Perry acquired 3,000 shares at a price of $5.89 per share, and Thaddeus Darden acquired 10,000 shares at a price of $5.80 per share. On December 12, 2023, Matthew Miller acquired 2,600 shares at a price of $5.93 per share. On January 3, 2024, pursuant to an award of restricted stock granted to each of the Company's director under the Company's 2022 Omnibus Incentive Plan, 8,813 shares of restricted Common Stock issued to each of Matthew Miller, Griffin Perry, Thaddeus Darden, and Kirk Lazarine vested. On March 14, 2025 and March 15, 2024, Matthew Miller acquired a total of 4,900 shares at prices ranging from $6.20 to $6.22 per share. On May 23, 2024, Griffin Perry acquired 2,000 shares at a price of $6.54 per share. On June 3, 2024 through June 17, 2024, Matthew Miller acquired a total of 16,683 shares at prices ranging from $5.90 to $6.50 per share. On June 6, 2024, Thaddeus Darden acquired 3,000 shares at a price of $6.29. On June 14, 2024, Thaddeus Darden acquired 7,000 shares at a price of $5.90 per share. On August 16, 2024, Matthew Miller acquired 4,938 shares at a price of $6.50 per share. On August 22, 2024, Matthew Miller acquired 4,000 shares at a price of $6,33 per share. On September 11, 2024, Matthew Miller acquired 8,500 shares at a price of $5.97 per share. On September 13, 2024, Matthew Miller acquired 495 shares at a price of $6.23 per share. On September 12, 2024, Griffin Perry acquired 5,000 shares at a price of $6.13 per share. On November 20, 2024, Matthew Miller acquired 18,173 shares at prices ranging from $6.47 to $6.53 per share. On November 21, 2024, Matthew Miller acquired 20,327 shares at prices ranging from $6.59 to $6.63 per share. On December 6, 2024, the following Filing Parties made open market acquisitions of shares of Common Stock: Thaddeus Darden acquired 9,440 shares at prices ranging from $6.10 to $6.13 per share. Matthew Miller acquired 31,000 shares at prices ranging from $6.05 to $6.12 per share. Except as set forth in this Schedule 13D, the Filing Parties do not have any plan or proposal that would relate to, or result in, any of the following matters: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above. Each of the Filing Parties reserve the right to propose or participate in future transactions which may result in one or more of the above listed actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the Common Stock to become eligible for termination of registration under Section 12(g) of the Act. The Filing Parties also retain the right to change their investment intent at any time, to acquire additional shares of Common Stock or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part of the Common Stock beneficially owned by them (or any shares of Common Stock into which such securities are converted) in any manner permitted by law. The Filing Parties may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. | 2026-08-21 |
| Ticker | Reporting Person | Type | Filing Date | Shares | % of Class | |
|---|---|---|---|---|---|---|
| HURA | James A. Bianco, M.D. | 13D/A | 2026-08-28 | 3.09M | 4.6% | |
| CBL | Amster Howard | 13D/A | 2026-08-28 | 2.41M | 7.8% | |
| GRX | Saba Capital Management, L.P. | 13D/A | 2026-08-28 | 2.16M | 14.3% | |
| QSI | ROTHBERG JONATHAN M | 13D/A | 2026-08-28 | 19.94M | 100.0% | |
| VIST | Miguel Matias Galuccio | 13D/A | 2026-08-28 | 6.74M | 6.1% | |
| RZLV | Daniel Maurice Wagner | 13D/A | 2026-08-28 | 55.03M | 13.8% | |
| CISS | Imperial Petroleum Inc. | 13D/A | 2026-08-28 | 6.14M | 80.5% | |
| GD | Longview Asset Management, LLC | 13D/A | 2026-08-28 | 27.10M | 10.0% | |
| MRM | Kouji Eguchi | 13D/A | 2026-08-28 | 2.03M | 25.1% | |
| LU | An Ke Technology Company Limited | 13D/A | 2026-08-28 | 1579.77M | 73.3% | |
| EVGN | L.I.A. Pure Capital Ltd. | 13D/A | 2026-08-28 | 3.06M | 19.4% | |
| SIEB | Gloria E. Gebbia | 13D/A | 2026-08-28 | 17.06M | 42.0% | |
| OPTU | Neil S. Subin | 13G/A | 2026-08-28 | 19.55M | 11.9% | |
| AUTL | Renata Kellnerova | 13D/A | 2026-08-28 | 14.78M | 5.6% | |
| PESI | MAK CAPITAL ONE LLC | 13G/A | 2026-08-28 | 1.02M | 4.8% | |
| BRUN | Sean Goodrich | 13D/A | 2026-08-28 | 5.14M | 10.3% | |
| ELPW | Orca Capital AG | 13G/A | 2026-08-28 | 48K | 4.9% | |
| JUNS | Orca Capital AG | 13G/A | 2026-08-28 | 40K | 3.3% | |
| CODA | Ezralow Bryan Ross | 13G/A | 2026-08-28 | 683K | 6.0% | |
| FUSB | Charles C. Anderson | 13D/A | 2026-08-28 | 143K | 2.6% | |
| NAUT | AH Bio Fund II, L.P. | 13D/A | 2026-08-28 | 7.68M | 6.0% | |
| EMPD | Streeterville Capital LLC | 13G/A | 2026-08-28 | 1.39M | 4.9% | |
| AIXI | Streeterville Capital LLC | 13G/A | 2026-08-28 | 5.52M | 9.9% | |
| MDWD | HOLD Alapkezelo Zrt. | 13G/A | 2026-08-28 | 1.35M | 10.4% | |
| AMRN | Sarissa Capital Management LP | 13D/A | 2026-08-27 | 25.74M | 6.1% | |
| GNK | Diana Shipping Inc. | 13D/A | 2026-08-27 | 4.42M | 10.1% | |
| CLST | Stilwell Activist Fund, L.P. | 13D/A | 2026-08-27 | 364K | 9.0% | |
| ETD | DGB Investment, Inc. | 13D/A | 2026-08-27 | 1.27M | 5.0% | |
| AMG BBH Asset-Backed Credit Fund, LLC | BROWN BROTHERS HARRIMAN & CO | 13D/A | 2026-08-27 | 2.40M | 60.9% | |
| NYC | Bellevue Capital Partners, LLC | 13D/A | 2026-08-27 | 1.99M | 62.9% | |
| BPRE | Saba Capital Management, L.P. | 13D/A | 2026-08-27 | 7.32M | 5.1% | |
| ADXN | Timothy Mark Dyer | 13D/A | 2026-08-27 | 19.10M | 9.0% | |
| Manulife Private Credit Plus Fund | John Hancock Life Insurance Company of New York | 13G/A | 2026-08-27 | 880K | 7.0% | |
| Manulife Private Credit Plus Fund | John Hancock Life Insurance Company (USA) | 13G/A | 2026-08-27 | 440K | 4.0% | |
| Manulife Private Credit Plus Fund | John Hancock Life & Health Insurance Company | 13G/A | 2026-08-27 | 880K | 7.0% | |
| Manulife Private Credit Plus Fund | Manulife Reinsurance (Bermuda) Limited | 13G/A | 2026-08-27 | 2.20M | 18.0% | |
| IMTX | Perceptive Advisors LLC | 13D/A | 2026-08-27 | 11.42M | 7.6% | |
| SCHL | Iole Lucchese | 13D/A | 2026-08-27 | 955K | 5.2% | |
| TBCH | DC VGA LLC | 13D/A | 2026-08-27 | 675K | 3.8% | |
| MSGY | Fung & Tun Limited | 13D/A | 2026-08-27 | 1.31M | 37.5% | |
| HZO | Renata Kellnerova | 13D/A | 2026-08-27 | 1.79M | 8.1% | |
| TACT | Charles M. Gillman | 13D/A | 2026-08-27 | 522K | 5.1% | |
| BNBX | KGPLA Holdings LLC | 13D/A | 2026-08-27 | 1.55M | 20.0% | |
| MKDW | Ming-Chia Huang | 13D/A | 2026-08-27 | 26.34M | 76.4% | |
| KRP | Rivercrest Capital Partners LP | 13D/A | 2026-08-27 | 8.00M | 7.3% | |
| VBIO | 3i, LP | 13D/A | 2026-08-27 | 3.33M | 9.9% | |
| PW | Bradley & Daytona Railway and Land Co. LLC | 13D/A | 2026-08-27 | 16K | 4.8% | |
| PESI | HOLD Alapkezelo Zrt. | 13G/A | 2026-08-27 | 2.25M | 10.6% | |
| PML | BANK OF AMERICA CORP /DE/ | 13D/A | 2026-08-26 | 4K | 79.5% | |
| PNI | BANK OF AMERICA CORP /DE/ | 13D/A | 2026-08-26 | 760 | 100.0% | |
| VRME | Stedham Adam H | 13D/A | 2026-08-26 | 1.02M | 7.4% | |
| VRME | GELLER MARSHALL S | 13D/A | 2026-08-26 | 591K | 4.5% | |
| ANY | Endeavor Blockchain, LLC | 13D/A | 2026-08-26 | 300K | 3.4% | |
| WW | Chernett Jorey | 13G/A | 2026-08-26 | 745K | 7.5% | |
| ASST | Vivek Ramaswamy | 13D/A | 2026-08-26 | 5.69M | 6.6% | |
| AEG | Vereniging Aegon | 13D/A | 2026-08-26 | 264.67M | 18.0% | |
| GETY | Getty Investments L.L.C. | 13D/A | 2026-08-26 | 191.37M | 45.5% | |
| Calamos Aksia Hedged Strategies Fund | Calamos Aksia Hedged Strategies Fund (Offshore), Ltd. | 13D/A | 2026-08-26 | 1.91M | 28.8% | |
| AUPH | ILJIN SNT Co., Ltd. | 13D/A | 2026-08-26 | 5.91M | 4.4% | |
| GETY | KED Icon Holdings, LLC | 13D/A | 2026-08-26 | 115.26M | 27.4% |